Revive Therapeutics Enters Exclusive License For Ganoderma Lucidum Intellectual Property
Revive Therapeutics (CSE: RVV) last night announced that it has has entered into an exclusive licensing agreement. The licensing agreement
Read more
Revive Therapeutics
Revive Therapeutics Provides Update On Current Psilocybin Programs
Revive Therapeutics (CSE: RVV) this morning provided a corporate update as it pertains to its psychedelic assets. The update primarily
Read more
Revive Therapeutics Begins Laying Groundwork For Commercialization Of Bucillamine
Revive Therapeutics (CSE: RVV) this afternoon reported that it is in the process of pursuing a commercialization plan for the
Read more
Revive Therapeutics Partners With University of Health Sciences Antigua To Further Psychedelics Research
Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a collaboration to further advance its psychedelic-assisted therapies.
Read more
Revive Therapeutics Looks To Bring Bucillamine To India
Revive Therapeutics (CSE: RVV) is looking to India. The company this morning indicated that it has entered into a memorandum
Read more
Revive Therapeutics Partners With UCSF To Study Bucillamine For Severe COVID-19
Revive Therapeutics (CSE: RVV) this morning had a major announcement, in that it has entered into a sponsored research agreement
Read more
Revive Therapeutics Applies For Orphan Drug Designation For Psilocybin
Revive Therapeutics (CSE: RVV) has filed for orphan drug designation with the US Food and Drug Administration. The filing relates
Read more
Revive Therapeutics Files For Patent On Oral Thin Film With Psilocybin
Revive Therapeutics (CSE: RVV) this morning announced that it has successfully completed research on an oral thin film delivery system
Read more
Revive Therapeutics Reports Successful Results Using Psilocybin To Treat Traumatic Brain Injury
Revive Therapeutics (CSE: RVV) this morning revealed that it has received positive results for a pre-clinical study that evaluated the
Read more
Revive Therapeutics To Expand Clinical Sites For Covid-19 Related Phase 3 Study
Revive Therapeutics (CSE: RVV) this morning provided an update on the status of its phase 3 clinical trial for the
Read more